Aging of the nitric oxide system: Are we as old as our NO?

Journal of the American Heart Association

Volumn 3, Issue 4, 2014, Pages

  Sverdlov, Aaron L ^a   Ngo, Doan T M ^a   Chan, Wai P A ^a   Chirkov, Yuliy Y ^a   Horowitz, John D ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Aging; Endothelium; Nitric oxide; Platelets

Indexed keywords

25 HYDROXYVITAMIN D; C REACTIVE PROTEIN; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; ARGININE; N,N-DIMETHYLARGININE;

ADULT; AGED; AGING; AMINO ACID BLOOD LEVEL; ARTICLE; BLOOD LEVEL; CARDIOVASCULAR RISK; CLINICAL EVALUATION; COHORT ANALYSIS; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; KIDNEY DYSFUNCTION; LIPID COMPOSITION; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; NITRIC OXIDE BLOOD LEVEL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; SEX DIFFERENCE; SIGNAL TRANSDUCTION; THROMBOCYTE AGGREGATION; TREND STUDY; VITAMIN BLOOD LEVEL; ANALOGS AND DERIVATIVES; CARDIOVASCULAR DISEASE; METABOLISM; MIDDLE AGED; THROMBOCYTE;

AGED; AGING; ARGININE; BLOOD PLATELETS; CARDIOVASCULAR DISEASES; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NITRIC OXIDE; PLATELET AGGREGATION; PROSPECTIVE STUDIES;

EID: 84931595456     PISSN: None     EISSN: 20479980     Source Type: Journal    
DOI: 10.1161/JAHA.114.000973     Document Type: Article

References (57)

1. Department of Economic and Social Affairs. Population Division. United Nations. World Population Ageing: 1950-2050. Department of Economic and Social Affairs. Population Division. United Nations; 2001.
2. Kovacic JC, Moreno P, Hachinski V, Nabel EG, Fuster V. Cellular senescence, vascular disease, and aging: Part 1 of a 2-part review. Circulation. 2011;123: 1650-1660.
3. Fleg JL, Gerstenblith G, Zonderman AB, Becker LC, Weisfeldt ML, Costa PT, Jr, Lakatta EG. Prevalence and prognostic significance of exercise-induced silent myocardial ischemia detected by thallium scintigraphy and electrocardiography in asymptomatic volunteers. Circulation. 1990;81:428-436.
4. Ngo DT, Sverdlov AL, Willoughby SR, Nightingale AK, Chirkov YY, McNeil JJ, Horowitz JD. Determinants of occurrence of aortic sclerosis in an aging population. JACC Cardiovasc Imaging. 2009;2:919-927.
5. Lakatta EG. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part III: cellular and molecular clues to heart and arterial aging. Circulation. 2003;107:490-497.
6. Lakatta EG, Levy D. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part II: the aging heart in health: links to heart disease. Circulation. 2003;107:346-354.
7. Chirkov YY, Horowitz JD. Impaired tissue responsiveness to organic nitrates and nitric oxide: a new therapeutic frontier? Pharmacol Ther. 2007;116:287-305.
8. Gao Y. The multiple actions of NO. Pflugers Arch. 2010;459:829-839.
9. Sverdlov AL, Chan WPA, Procter NEK, Chirkov YY, Ngo DTM, Horowitz JD. Reciprocal regulation of no signaling and txnip expression in humans: impact of aging and ramipril therapy. Int J Cardiol. 2013;168:4624-4630.
10. Sverdlov AL, Ngo DT, Nightingale AK, Rajendran S, Mishra K, Heresztyn T, Ritchie RH, Marwick TH, Frenneaux MP, Horowitz JD. The endogenous nos inhibitor asymmetric dimethylarginine (ADMA) predicts LV mass independent of afterload. Nitric Oxide. 2011;25:41-46.
11. Sibal L, Agarwal SC, Home PD, Boger RH. The role of asymmetric dimethylarginine (ADMA) in endothelial dysfunction and cardiovascular disease. Curr Cardiol Rev. 2010;6:82-90.
12. Ngo DT, Sverdlov AL, McNeil JJ, Horowitz JD. Does vitamin D modulate asymmetric dimethylarginine and c-reactive protein concentrations? Am J Med. 2010;123:335-341.
13. Willoughby SR, Stewart S, Holmes AS, Chirkov YY, Horowitz JD. Platelet nitric oxide responsiveness: a novel prognostic marker in acute coronary syndromes. Arterioscler Thromb Vasc Biol. 2005;25:2661-2666.
14. Marliss EB, Chevalier S, Gougeon R, Morais JA, Lamarche M, Adegoke OA, Wu G. Elevations of plasma methylarginines in obesity and ageing are related to insulin sensitivity and rates of protein turnover. Diabetologia. 2006;49:351-359.
15. Chan WP, Ngo DT, Sverdlov AL, Rajendran S, Stafford I, Heresztyn T, Chirkov YY, Horowitz JD. Premature aging of cardiovascular/platelet function in polycystic ovarian syndrome. Am J Med. 2013;126:e641-e647.
16. Grant JF, Chittleborough CR, Taylor AW, Dal GRANDE E, Wilson DH, Phillips PJ, Adams RJ, Cheek J, Price K, Gill T, Ruffin RE. The North West Adelaide Health Study: detailed methods and baseline segmentation of a cohort for selected chronic diseases. Epidemiol Perspect Innov. 2006;3:4
17. Chirkov YY, Holmes AS, Willoughby SR, Stewart S, Horowitz JD. Association of aortic stenosis with platelet hyperaggregability and impaired responsiveness to nitric oxide. Am J Cardiol. 2002;90:551-554.
18. Wilkinson IB, Cockcroft JR, Webb DJ. Pulse wave analysis and arterial stiffness. J Cardiovasc Pharmacol. 1998;32(suppl 3):S33-S37.
19. Wilkinson IB, MacCallum H, Flint L, Cockcroft JR, Newby DE, Webb DJ. The influence of heart rate on augmentation index and central arterial pressure in humans. J Physiol. 2000;525(Pt 1):263-270.
20. Weber T, Auer J, O'Rourke MF, Kvas E, Lassnig E, Berent R, Eber B. Arterial stiffness, wave reflections, and the risk of coronary artery disease. Circulation. 2004;109:184-189.
21. Heresztyn T, Worthley MI, Horowitz JD. Determination of L-arginine and NG, NG-and NG, NG0-dimethyl-L-arginine in plasma by liquid chromatography as accq-fluor fluorescent derivatives. J Chromatogr B Analyt Technol Biomed Life Sci. 2004;805:325-329.
22. Geiger J. Inhibitors of platelet signal transduction as anti-aggregatory drugs. Expert Opin Investig Drugs. 2001;10:865-890.
23. McEniery CM, Wallace S, Mackenzie IS, McDonnell B, Yasmin, Newby DE, Cockcroft JR, Wilkinson IB. Endothelial function is associated with pulse pressure, pulse wave velocity, and augmentation index in healthy humans. Hypertension. 2006;48:602-608
24. Horowitz JD, Heresztyn T. An overview of plasma concentrations of asymmetric dimethylarginine (ADMA) in health and disease and in clinical studies: methodological considerations. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;851:42-50.
25. Muller FL, Lustgarten MS, Jang Y, Richardson A, Van Remmen H. Trends in oxidative aging theories. Free Radic Biol Med. 2007;43:477-503.
26. Lee S, Kim SM, Lee RT. Thioredoxin and thioredoxin target proteins: from molecular mechanisms to functional significance. Antioxid Redox Signal. 2013;18:1165-1207.
27. Roberts DD, Miller TW, Rogers NM, Yao M, Isenberg JS. The matricellular protein thrombospondin-1 globally regulates cardiovascular function and responses to stress via CD47. Matrix Biol. 2012;31:162-169.
28. Rogers NM, Roberts DD, Isenberg JS. Age-associated induction of cell membrane CD47 limits basal and temperature-induced changes in cutaneous blood flow. Ann Surg. 2013;258:184-191.
29. Yao M, Rogers NM, Csanyi G, Rodriguez AI, Ross MA, St Croix C, Knupp H, Novelli EM, Thomson AW, Pagano PJ, Isenberg JS. Thrombospondin-1 activation of signal-regulatory protein-alpha stimulates reactive oxygen species production and promotes renal ischemia reperfusion injury. J Am Soc Nephrol. 2014;25:1171-1186.
30. Miller TW, Isenberg JS, Roberts DD. Thrombospondin-1 is an inhibitor of pharmacological activation of soluble guanylate cyclase. Br J Pharmacol. 2010;159:1542-1547.
31. Willoughby SR, Rajendran S, Chan WP, Procter N, Leslie S, Liberts EA, Heresztyn T, Chirkov YY, Horowitz JD. Ramipril sensitizes platelets to nitric oxide: implications for therapy in high-risk patients. J Am Coll Cardiol. 2012;60:887-894.
32. Ngo DT, Sverdlov AL, McNeil JJ, Horowitz JD. Correlates of arterial stiffness in an ageing population: role of asymmetric dimethylarginine. Pharmacol Res. 2009;60:503-507.
33. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation. 2000;101:1899-1906.
34. Lee LV, Foody JM. Women and heart disease. Cardiol Clin. 2011;29:35-45.
35. Yee DL, Sun CW, Bergeron AL, Dong JF, Bray PF. Aggregometry detects platelet hyperreactivity in healthy individuals. Blood. 2005;106:2723-2729.
36. McGreevy C, Williams D. New insights about vitamin D and cardiovascular disease: a narrative review. Ann Intern Med. 2011;155:820-826.
37. Kielstein JT, Bode-Boger SM, Frolich JC, Ritz E, Haller H, Fliser D. Asymmetric dimethylarginine, blood pressure, and renal perfusion in elderly subjects. Circulation. 2003;107:1891-1895.
38. Hov GG, Sagen E, Bigonah A, Asberg A. Health-associated reference values for arginine, asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA) measured with high-performance liquid chromatography. Scand J Clin Lab Invest. 2007;67:868-876.
39. Holden DP, Cartwright JE, Nussey SS, Whitley GS. Estrogen stimulates dimethylarginine dimethylaminohydrolase activity and the metabolism of asymmetric dimethylarginine. Circulation. 2003;108:1575-1580.
40. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet. 1992;339:572-575.
41. Abbasi F, Asagmi T, Cooke JP, Lamendola C, McLaughlin T, Reaven GM, Stuehlinger M, Tsao PS. Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus. Am J Cardiol. 2001;88:1201-1203.
42. Boger RH, Bode-Boger SM, Szuba A, Tsao PS, Chan JR, Tangphao O, Blaschke TF, Cooke JP. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: Its role in hypercholesterolemia. Circulation. 1998;98:1842-1847.
43. Achan V, Broadhead M, Malaki M, Whitley G, Leiper J, MacAllister R, Vallance P. Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler Thromb Vasc Biol. 2003;23:1455-1459.
44. Blackwell S. The biochemistry, measurement and current clinical significance of asymmetric dimethylarginine. Ann Clin Biochem. 2010;47:17-28.
45. Tain YL, Baylis C. Determination of dimethylarginine dimethylaminohydrolase activity in the kidney. Kidney Int. 2007;72:886-889.
46. Sakurada M, Shichiri M, Imamura M, Azuma H, Hirata Y. Nitric oxide upregulates dimethylarginine dimethylaminohydrolase-2 via cyclic GMP induction in endothelial cells. Hypertension. 2008;52:903-909.
47. Antoniades C, Shirodaria C, Leeson P, Antonopoulos A, Warrick N, Van-Assche T, Cunnington C, Tousoulis D, Pillai R, Ratnatunga C, Stefanadis C, Channon KM. Association of plasma asymmetrical dimethylarginine (ADMA) with elevated vascular superoxide production and endothelial nitric oxide synthase uncoupling: implications for endothelial function in human atherosclerosis. Eur Heart J. 2009;30:1142-1150.
48. Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res. 2000;86:494-501.
49. Satoh M, Fujimoto S, Haruna Y, Arakawa S, Horike H, Komai N, Sasaki T, Tsujioka K, Makino H, Kashihara N. NAD(P)H oxidase and uncoupled nitric oxide synthase are major sources of glomerular superoxide in rats with experimental diabetic nephropathy. Am J Physiol Renal Physiol. 2005;288: F1144-F1152.
50. Monteiro PF, Morganti RP, Delbin MA, Calixto MC, Lopes-Pires ME, Marcondes S, Zanesco A, Antunes E. Platelet hyperaggregability in high-fat fed rats: a role for intraplatelet reactive-oxygen species production. Cardiovasc Diabetol. 2012;11:5.
51. Sverdlov AL, Ngo DT, Chan WP, Chirkov YY, Gersh BJ, McNeil JJ, Horowitz JD. Determinants of aortic sclerosis progression: implications regarding impairment of nitric oxide signalling and potential therapeutics. Eur Heart J. 2012;33:2419-2425.
52. Burgoyne JR, Prysyazhna O, Rudyk O, Eaton P. cGMP-dependent activation of protein kinase g precludes disulfide activation: Implications for blood pressure control. Hypertension. 2012;60:1301-1308.
53. O'Donnell CJ, Larson MG, Feng D, Sutherland PA, Lindpaintner K, Myers RH, D'Agostino RA, Levy D, Tofler GH; Framingham Heart S. Genetic and environmental contributions to platelet aggregation: the Framingham heart study. Circulation. 2001;103:3051-3056.
54. Origlia C, Pescarmona G, Capizzi A, Cogotti S, Gambino R, Cassader M, Benso A, Granata R, Martina V. Platelet cGMP inversely correlates with age in healthy subjects. J Endocrinol Invest. 2004;27:RC1-RC4
55. Kane GC, Karon BL, Mahoney DW, Redfield MM, Roger VL, Burnett JC, Jr, Jacobsen SJ, Rodeheffer RJ. Progression of left ventricular diastolic dysfunction and risk of heart failure. JAMA. 2011;306:856-863.
56. Silberman GA, Fan TH, Liu H, Jiao Z, Xiao HD, Lovelock JD, Boulden BM, Widder J, Fredd S, Bernstein KE, Wolska BM, Dikalov S, Harrison DG, Dudley SC, Jr. Uncoupled cardiac nitric oxide synthase mediates diastolic dysfunction. Circulation. 2010;121:519-528.
57. Ritchie RH, Irvine JC, Rosenkranz AC, Patel R, Wendt IR, Horowitz JD, Kemp-Harper BK. Exploiting cGMP-based therapies for the prevention of left ventricular hypertrophy: NO* and beyond. Pharmacol Ther. 2009;124:279-300.